<sup>18</sup>F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

Vandenberghe, Rik; Laere, Koen Van; Ivanoiu, Adrian; Salmon, Eric; Bastin, Christine; Triau, Eric; Hasselbalch, Steen G.; Law, Ian; Andersen, Allan; Kørner, Alex; Minthon, Lennart; Garraux, Gaëtan; Nelissen, Natalie; Bormans, Guy; Buckley, Chris; Owenius, Rikard; Thurfjell, Lennart; Farrar, Gill; Brooks, David J.

doi:10.1002/ana.22068

Cited by 604 publications

(562 citation statements)

References 32 publications

Supporting

Mentioning

519

Contrasting

Unclassified

Order By: Relevance

“…There are four PET imaging agents that have been well-studied in humans: [ 11 C]PIB, 2 florbetapir f18 (Amyvid), 3,4 florbetaben f18, 5 and flutemetamol f18 6 (Figure 2A). Results of a phase 3 Figure 2B).…”

Section: ■ Aβ Plaque-specific Imaging For Diagnosis and Drug Developmentmentioning

confidence: 99%

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

Kung

2012

ACS Med. Chem. Lett.

103

View full text Add to dashboard Cite

Section: ■ Aβ Plaque-specific Imaging For Diagnosis and Drug Developmentmentioning

confidence: 99%

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

Kung

2012

ACS Med. Chem. Lett.

103

View full text Add to dashboard Cite

“…The study also compared the performance of flutemetamol to PIB with cortical SUVRs for these patients ranging from 0.89 to 0.92. There was a low degree of test-retest variability, indicating precision of this biomarker [31]. These initial trials led to the favorable promise of flutemetamol given its structural similarity to PIB, reproducibility, and diagnostic capabilities.…”

Section: [ 18 F]3'-f-pib or Flutemetamolmentioning

confidence: 96%

Amyloid Imaging: Poised for Integration into Medical Practice

Anand

Sabbagh

2017

Neurotherapeutics

View full text Add to dashboard Cite

Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer's disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, 11 C-PIB was developed, which was the prototype for many 18 F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date.

show abstract

“…F-labeled compounds ( Fig. 1) (Liu, Kepe et al 2007;Choi, Golding et al 2009;Jureus, Swahn et al 2010;Vandenberghe, Van Laere et al 2010;Barthel, Gertz et al 2011;Clark, Schneider et al 2011 …”

Section: Introductionmentioning

confidence: 99%

Radiosynthesis and in vivo evaluation of a 18F-labelled styryl-benzoxazole derivative for β-amyloid targeting

Morais¹,

Gano²,

Knieß

et al. 2013

Applied Radiation and Isotopes

View full text Add to dashboard Cite

The formation of β-amyloid deposits is considered a histopathological feature of Alzheimer´s disease (AD). In vivo molecular imaging by means of amyloid-avid radiotracers will allow for an early and conclusive diagnostic of AD. Herein, we describe the radiosynthesis of the radiofluorinated styryl benzoxazole derivative Highlights• Design of a fluorinated styryl benzoxazole derivative for detection of β-amyloid plaques.• Nucleophilic radiofluorination with readily available [ 18 F]KF.• Metabolism and biodistribution studies of the radiofluorinated styryl benzoxazole derivative.

show abstract

¹⁸F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

Abstract: (18)F-Flutemetamol performs similarly to the (11)C-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use.

Cited by 604 publications

References 32 publications

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

Amyloid Imaging: Poised for Integration into Medical Practice

Radiosynthesis and in vivo evaluation of a 18F-labelled styryl-benzoxazole derivative for β-amyloid targeting

Contact Info

Product

Resources

About

18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

Abstract: (18)F-Flutemetamol performs similarly to the (11)C-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use.

Cited by 604 publications

References 32 publications

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing

Amyloid Imaging: Poised for Integration into Medical Practice

Radiosynthesis and in vivo evaluation of a 18F-labelled styryl-benzoxazole derivative for β-amyloid targeting

Contact Info

Product

Resources

About

¹⁸F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial